

REVISED 11/2015			(germ cell tumor).
Date written	To begin		_ J Clin Oncol 1998;16:1287-93.
Patient's: Heightcm	Weight kg	BSA m ²	
Allergies: •No	Weightkg	D 5/1III	
Diagnosis			
			-1
1. Laboratory Studies:	n to finat does of abome		
_	r to first dose of chemo		
	eeded prior to first dose cher		c.
2. Consent Obtained?	orior to chemo, Urinalysis (m	iacroscopic omy) Qsim	ıı
	1 Canaant		
Yes Preprinted	Consent		
3. Hydration:	T :fa4 500 T /h	. 2 h auna mua aismla <i>ti</i> m	an day 1 than via continuous
		. 2 nours pre-cispiaun	on day 1, then via continuous
infusion at 100 ml/h 4. Premedications:	ir on days 1-5		
Ondansetron 16 mg IV q24hr prior to chemotherapy on Days 1-5			
Dexamethasone 10 mg IV q 24hr prior to chemotherapy Days 1-5 Aprepitant 125 mg po day 1			
·			
Aprepitant 80 mg p			
5. Chemotherapy dose	calculation:		
Etoposide 75 mg/m	$^2 = $ mg IV in 500) mL NS over 60 minu	ites q24hr on days 1-5
Cisplatin 20 mg/m ²	=mg IV in 150	mL NS, infuse over 3	60 minutes q24h on days 1-5
	Mesna- flush tubing before		• •
Mesna 120 mg/m² =	mg IV in 50 n	nL D5W infuse over 1	5 minutes before ifosfamide on day
1 only		III DO VV III USC OVET I	e inimates serore nostamae on aug
·	•		
Ifosfamide 1200 mg	$m^2 = \underline{\qquad} mg IV$	in 250 mL NS, infuse	e over 1 hour q24h on days 1-5
Mesna 1200 mg/m ²	=mg IV in 1	IL NS, infuse via cont	inuous infusion q24hr on days 1-5.
6. Post-discharge care:			-
Dexamethasone 4 mg	g PO BID on Days 6-8		
Ondansetron 8 mg P	O BID on Days 6-8		
Prochlorperazine 10	mg PO Q6hr PRN nausea/v	omiting	
Pegfilgrastim 1 6	mg subcutaneously day 6 o	or 7 of chemo regimen	L
6	mg subcutaneously via OI	BI to be placed day 5 (or at discharge from hospital
Laboratory studies:	CBC Weekly, fax results to	#717-531-4969.	·
	MD/Prep	oarer's Signature	
	Attending Phy	sician Signature	

